NASDAQ · Drug Manufacturers - Specialty & Generic

Cyclo Therapeutics, Inc. (CYTH) Stock

$0.72 +0.00% NASDAQ: CYTH Healthcare

Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions.

Valuation

MetricValue
Price$0.72
Market Cap$23.59M
P/E Ratio-0.59
P/B Ratio2.47
P/S Ratio21.92
EPS (TTM)$-1.23
52-Week High$1.62
52-Week Low$0.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-730.48%
ROA-151.40%
ROCE-419.50%
Gross Margin90.85%
Operating Margin-2000.00%
Net Margin-2000.00%
Debt/Equity0.22
Current Ratio1.45

Annual Financials (USD)

Metric20192020202120222023
Revenue$1.0M$1.0M$2.0M$1.0M$1.0M
Operating Profit$-7.0M$-9.0M$-14.0M$-16.0M$-20.0M
Net Profit$-8.0M$-9.0M$-14.0M$-15.0M$-20.0M
EPS$-7.09$-5.58$-2.25$-1.81$-1.23
Op Margin-733.8%-991.9%-899.8%-1134.8%-1862.7%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$4.0M$14.0M$20.0M$4.0M$13.0M
Total Liabilities$3.0M$4.0M$4.0M$3.0M$8.0M
Cash$3.0M$13.0M$17.0M$2.0M$9.0M
Borrowings$0$0$0$0$1.0M

Latest News

New Mideast fighting puts eurozone rate-setters on alert AFP · Jul 23, 2026 Dow Jones Futures Rise; Google, Tesla Fall On Earnings, Capex, But AI Stocks Climb Investor's Business Daily · Jul 23, 2026 What's the deal with peptides? The hyped market under US review AFP · Jul 23, 2026 TowneBank Reports Second Quarter 2026 Earnings GlobeNewswire · Jul 23, 2026 Pichai pushes back on claims Google is losing ground in AI race Reuters · Jul 23, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-7.0M$-9.0M$-15.0M$-15.0M$-16.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$14.0M
Net Cash Flow$1.0M$10.0M$4.0M$-15.0M$8.0M
Free Cash Flow$-7.0M$-9.0M$-15.0M$-15.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.77
FCF Yield-68.62%
Quick Ratio1.42
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ELEVElevation Oncology, Inc. $0.37 -2.12% -0.47 $21.63M 0.00%
ELUT $0.86 -5.33% -1.24 $37.88M 0.00%
HEXOHEXO Corp. $0.71 +2.45% -0.03 $31.24M 0.00%
IVCInvacare Corporation $0.66 +0.00% -0.24 $24.91M 0.00%
LSBLakeShore Biopharma Co., Ltd $0.63 +0.00% -4.51 $25.84M 0.00%

About Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.

Cyclo Therapeutics, Inc. is headquartered in US.

Cyclo Therapeutics, Inc. (CYTH) stock trades at $0.72 with a market capitalization of $23.59M. The stock is valued at a price-to-earnings (P/E) ratio of -0.59, price-to-book of 2.47, price-to-sales of 21.92. Over the past 52 weeks the stock has ranged between $0.55 and $1.62, and currently trades 55.6% below its 52-week high.

On profitability, Cyclo Therapeutics, Inc. generates a return on equity (ROE) of -730.48%, return on capital employed of -419.50%, an operating margin of -2000.00%, a net profit margin of -2000.00%.

Official website: www.cyclotherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides